INDP · Indaptus Therapeutics, Inc. · Executive Compensation
$2.60
+0.09 (+3.59%)
At close · Oct 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result of these uncertainties, there is substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$512.98M
Shares
133.24M
Volume · Oct 5
361.48K
Avg daily vol (3M)
808.65K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Jeffrey A. Meckler | Chief Executive Office ^)^ | $1,001,249 |
| Walt A. Linscott | Esq., Chief Operating Officer | $770,039 |
| Michael J. Newman | Chief Scientific Officer | $718,039 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Jeffrey A. Meckler | Chief Executive Office ^)^ | $1,680,532 |
| Walt A. Linscott | Esq., Chief Operating Officer | $848,244 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Jeffrey A. Meckler | Chief Executive Officer | $1,412,237 |
| Jeffrey Meckler | Chief Executive Officer | $1,412,237 |
| Walt A. Linscott | Esq., Chief Business Officer | $1,091,642 |
| Michael J. Newman | Chief Scientific Officer | $851,856 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Jeffrey Meckler | Chief Executive Officer | $1,066,243 |
| Jeffrey A. Meckler | Chief Executive Officer | $1,066,243 |
| Walt A. Linscott | Esq., Chief Business Officer | $789,183 |
| Michael J. Newman | Chief Scientific Officer | $200,000 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Tim Ruan | Board | Resigned | 2026-09-04 |
| Avraham Ben-Tzvi | Director | Resigned | 2026-06-05 |
| Walt A. Linscott, Esq. | Chief Operating Officer | Resigned | 2026-06-05 |
| David E. Lazar | Director | Resigned | 2026-06-05 |
| Matthew McMurdo | director | Resigned | 2026-04-23 |
| Yi Zhang | independent director | Appointed | 2026-04-23 |
| Tim Ruan | independent director | Appointed | 2026-04-23 |
| Yu Ding | Chief Financial Officer | Appointed | 2026-04-03 |
| Qinglai Lu | member of the Board of Directors | Appointed | 2026-04-03 |
| Nir Sassi | Chief Financial Officer | Resigned | 2026-04-03 |
| Junyi Dai | Chairman of the Board of Directors | Appointed | 2026-03-24 |
| William B. Hayes | Director | Resigned | 2026-03-24 |
| David Lazar | co-Chief Executive Officer | Resigned | 2026-03-24 |
| Roger J. Pomerantz | Director | Resigned | 2026-03-24 |
| Anthony J. Maddaluna | Director | Resigned | 2026-03-24 |
| Jeffrey A. Meckler | co-Chief Executive Officer | Resigned | 2026-03-24 |
| Jeffrey A. Meckler | Director | Resigned | 2026-03-24 |
| David Natan | Class II director | Appointed | 2026-01-08 |
| Anthony Maddaluna | member of the Board of Directors | Resigned | 2026-01-02 |
| Mark Gilbert | member of the Board of Directors | Resigned | 2026-01-02 |
| Michael Newman | member of the Board of Directors | Resigned | 2026-01-02 |
| Roger J. Waltzman, M.D. | Chief Medical Officer | Resigned | 2025-12-23 |
| Avraham Ben-Tzvi | member of the Board of Directors | Appointed | 2025-12-23 |
| David Lazar | member of the Board of Directors | Appointed | 2025-12-23 |
| David Lazar | Co-Chief Executive Officer | Appointed | 2025-12-23 |